Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Gareth W. Harbottle"'
Autor:
Johann S. de Bono, Neil Pegg, Karen E. Knudsen, Matthew J. Schiewer, David Taddei, Amanda Swain, Jian Ning, Antje J. Neeb, Suzanne Carreira, Nina Tunariu, Rita Pereira, Ana Ferreira, Mateus Crespo, Susana Miranda, Veronica S. Gil, Gareth W. Harbottle, Don Smyth, Richard Brown, Silvia Paoletta, Jonathan Shannon, Stuart Onions, Jenny Worthington, Stuart Thomson, Jordan Lane, Amy Prosser, Meera Raja, Barbara Young, William West, Denisa Bogdan, Jan Rekowski, Bora Gurel, Ruth Riisnaes, Ines Figueiredo, Abhijit Pal, Saswati N. Chand, Christopher McNair, Wei Yuan, Nigel Brooks, Adam Sharp, Jonathan Welti
Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV). Inhibitors of transcriptional coactivators that regulate AR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c73d8a93c6f4a3feb2612ceef314ced
https://doi.org/10.1158/2159-8290.c.6549379
https://doi.org/10.1158/2159-8290.c.6549379
Autor:
Johann S. de Bono, Neil Pegg, Karen E. Knudsen, Matthew J. Schiewer, David Taddei, Amanda Swain, Jian Ning, Antje J. Neeb, Suzanne Carreira, Nina Tunariu, Rita Pereira, Ana Ferreira, Mateus Crespo, Susana Miranda, Veronica S. Gil, Gareth W. Harbottle, Don Smyth, Richard Brown, Silvia Paoletta, Jonathan Shannon, Stuart Onions, Jenny Worthington, Stuart Thomson, Jordan Lane, Amy Prosser, Meera Raja, Barbara Young, William West, Denisa Bogdan, Jan Rekowski, Bora Gurel, Ruth Riisnaes, Ines Figueiredo, Abhijit Pal, Saswati N. Chand, Christopher McNair, Wei Yuan, Nigel Brooks, Adam Sharp, Jonathan Welti
Supplementary figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d313da933b889d09a6fcaf5a2385ff7
https://doi.org/10.1158/2159-8290.22540441.v1
https://doi.org/10.1158/2159-8290.22540441.v1
Autor:
Matthew J. Schiewer, Susana Miranda, William West, Suzanne Carreira, Stuart Thomson, Gareth W. Harbottle, Ana Ferreira, Stuart Thomas Onions, Donald Smyth, Nigel Brooks, Jonathan Shannon, Jonathan Welti, Nina Tunariu, Johann S. de Bono, Christopher McNair, Jenny Worthington, Wei Yuan, Karen E. Knudsen, Adam Sharp, Barbara Young, Amy Prosser, Jan Rekowski, Su C, Rita Pereira, Amanda Swain, Jian Ning, Abhijit Pal, Jordan Lane, Ruth Riisnaes, Bora Gurel, Ines Figueiredo, Mateus Crespo, Richard J. C. Brown, Saswati N. Chand, David Michel Adrien Taddei, Denisa Bogdan, Veronica Gil, Silvia Paoletta, Meera Raja, Neil Anthony Pegg, Antje Neeb
Publikováno v:
Cancer discovery. 11(5)
Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV). Inhibitors of transcriptional coactivators that regulate AR
Autor:
George Procopiou, Gareth W. Harbottle, Robert A. Stockman, Diane Robbins, William Lewis, P. Aggarwal
Publikováno v:
Synlett. 23:423-427
Both two-directional synthesis and tandem reactions are able to form several bonds in a single transformation, making them excellent reaction types to build molecular complexity. Over the past decade, we have had an ongoing interest in combining thes
Autor:
Gareth W. Harbottle, Daniel Laity, Stuart Field, Kenneth John Butcher, Benjamin A. Pibworth, Adam T. Gillmore, Christian J. Ngono, Steven M. Denton, Roger M. Howard
Publikováno v:
Organic Process Research & Development. 15:1192-1200
The convergent scale-up synthesis of two complex TRPV1 antagonists to support exploratory toxicology studies is described. Both compounds contain three chiral centers introduced by asymmetric synthesis with chiral control being critical for the succe
Autor:
William A. Million, Pauline Carnell, Gareth W. Harbottle, Russell Monhemius, Simon A. Osborne, Cedric Poinsard, Maw Graham Nigel, Ben S. Greener, Karl Richard Gibson, Rebecca L. Prime, Steven England, Peter G. Dodd, Simon John Mantell, Alison Betts, Huw Rees
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:2190-2194
The SAR of a series of novel pyrido[3,4-d]pyramid-4-ylamine mGluR1 antagonists is described. The multiple of the unbound K(i) in cerebrospinal fluid necessary to give morphine like analgesic effects in an electromyograph pinch model in rodents is det
Autor:
Gareth W. Harbottle, Maw Graham Nigel, Cedric Poinsard, Simon A. Osborne, Neil Feeder, Karl Richard Gibson, Mel Glossop, Florence F. Morel, William A. Million
Publikováno v:
Tetrahedron Letters. 48:4293-4296
The syntheses of 6-fluoropyrido[3,4-d]pyrimidin-4-ylamine derivatives is reported herein. Methods for generating C, N and O linked analogues under microwave irradiation are described.
Autor:
Simon Gayton, Graham Smith, Dafydd R. Owen, Gareth W. Harbottle, Tracy J. Ringer, Maw Graham Nigel, Simon A. Osborne, Margarita Rodriguez-Lens, Huw Rees, Peter G. Dodd, Ben S. Greener, Simon John Mantell
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:486-490
A series of novel mGluR1 antagonists have been prepared. Incorporation of fragments derived from weak lead matter into a library led to enhanced potency in a new chemical series. A chemistry driven second library iteration, covering a greatly enhance
Autor:
Gareth W. Harbottle, Robert A. Stockman, Annabella F. Newton, David Richards, Ian R. Mellor, George Procopiou, P. Aggarwal
© 2014 The Royal Society of Chemistry. The first total synthesis of myrmicine ant alkaloid 5-epi-cis-275B′ (4) is presented. A tandem cyclisation established the entire core of the structure in a single transformation as well as the required 2,5-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c13becfd3d3c055f3d8ac39c95e3511
Autor:
Amy Prosser, Karen E. Knudsen, Gareth W. Harbottle, Jenny Worthington, Jordan Lane, Nigel Brooks, Richard J. C. Brown, David Michel Adrien Taddei, Barbara Young, Neil Anthony Pegg, Silvia Paoletta, Jonathan Shannon
Publikováno v:
Journal of Clinical Oncology. 35:11590-11590
11590 Background: Targeted degradation of androgen receptor (AR) and AR variants (ARV) remains an attractive therapeutic opportunity for patients with castrate resistant prostate cancer (CRPC). E1A binding protein (p300) and CREB binding protein (CBP